hello world!
A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold-standard cancer screening procedure.
The protocol required 25,000 average-risk patients between the ages of 45 and 85 to enroll. The sponsor also looked to include a diverse and representative population in the trial.
See how the Science 37 Direct-to-Patient Site enrolled nearly 50% of the entire study with 24.2% minority representation, enabling recruitment and access across 49 states. This accelerated approach resulted in a more than 3-year reduction of the clinical trial timeline.
Submit the form to watch the case study video.
